Journal of Thrombosis and Thrombolysis最新文献

{"title":"miR-224-5p alleviates oxygen-glucose deprivation/reperfusion injury via regulating FAS.","authors":"Yanping Zhu, Haitao Fang, Yawen Zhang, Yu Zhang","doi":"10.1007/s11239-026-03397-y","DOIUrl":"https://doi.org/10.1007/s11239-026-03397-y","url":null,"abstract":"<p><p>miR-224-5p is downregulated in patients with cerebral infarction (CI); however, its diagnostic value and underlying mechanisms remain to be fully elucidated. The present investigation sought to explore the potential auxiliary diagnostic value of serum miR-224-5p between CI patients and healthy volunteers, and clarify its regulatory mechanism. Serum levels of miR-224-5p and FAS were quantified in CI patients via qRT-PCR. ROC curve analysis was utilized to evaluate the diagnostic efficacy of miR-224-5p in CI, while a binary logistic regression model was employed to identify variables associated with elevated CI risk. CCK-8, flow cytometry, and ELISA were employed to measure cell viability, apoptosis rate, and inflammatory factor levels, respectively. Bioinformatics analysis, coupled with a dual-luciferase reporter assay, was performed to validate the miR-224-5p target gene. miR-224-5p was markedly downregulated in CI patients, and this molecule showed moderate discriminatory ability to distinguish CI patients from healthy controls with an AUC of 0.827, which only reflects its differentiation efficiency versus healthy population rather than other neurological disorders. Reduced miR-224-5p expression, diabetes mellitus and hyperlipidemia were significantly linked to higher risk of CI. In the OGD/R cell model, miR-224-5p upregulation reversed the injury phenotypes, including decreased cell viability, increased apoptosis rate, and aggravated inflammatory response. miR-224-5p directly targets FAS. FAS exhibited marked overexpression in CI patient serum and bore a negative correlation with miR-224-5p expression. FAS overexpression elicited reduced cell viability, elevated apoptosis rate, and triggered an inflammatory response. Serum miR-224-5p could serve as a potential auxiliary biomarker for distinguishing CI patients from healthy individuals in single-center cohort; further multi-center validation and disease control groups are required to confirm its clinical diagnostic performance.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149030946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DWI-FLAIR mismatch versus perfusion-based selection for extended window thrombolysis in acute ischemic stroke: a meta-analysis of randomized controlled trials.","authors":"Jagkirat Singh, Victor Hugo Pinheiro Lopes, Marianna Leite, Gustavo Nascimento de Medeiros, Julie de Lima Loiola, Luisa Medeiros Visentini, Ocílio Ribeiro Gonçalves, Amit Bansal, Leonardo Di Cosmo","doi":"10.1007/s11239-026-03396-z","DOIUrl":"10.1007/s11239-026-03396-z","url":null,"abstract":"<p><p>To compare efficacy and safety outcomes of DWI-FLAIR mismatch versus CT/MR perfusion-based selection for intravenous thrombolysis (IVT) in extended-window acute ischemic stroke (AIS), we performed a systematic review and meta-analysis of randomized controlled trials enrolling adults with acute ischemic stroke treated with imaging-selected IVT beyond 4.5 h from last known well or with unknown onset. Trials using DWI-FLAIR mismatch or CT/MR perfusion selection were included. Outcomes were excellent functional outcome, functional independence, symptomatic intracranial hemorrhage (sICH), parenchymal hematoma, major bleeding, and mortality. Random-effects pairwise meta-analysis and Bucher-type indirect comparison were performed. Eight randomized trials including 2,546 patients were analyzed. Compared with best medical treatment, IVT improved excellent functional outcome (mRS 0-1: RR 1.27, 95% CI 1.14-1.40) and functional independence (mRS 0-2: RR 1.15, 95% CI 1.07-1.23), but increased sICH (RR 5.21, 95% CI 2.25-12.04). In imaging-stratified analyses, functional outcome RRs favored IVT in both perfusion-based and DWI-FLAIR mismatch-selected trials, with wider confidence intervals in the DWI-FLAIR subgroup. Hemorrhagic risk was increased with intravenous thrombolysis in both imaging subgroups, but subgroup interaction testing and a Bucher-type indirect comparison did not detect a statistically significant between-paradigm difference; the indirect comparison re-expresses the subgroup contrast rather than adding independent evidence. In AIS patients not planned for routine endovascular therapy, imaging-selected IVT beyond 4.5 h was associated with improved functional outcomes but increased sICH risk. No definitive superiority or equivalence was established between imaging strategies; imaging choice should be guided by clinical context, time window, EVT eligibility, local workflow, and patient-level factors.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149002122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Pulmonary Embolism Comprehensive Screening Scoring (PECSS) using multi-center emergency cohorts.","authors":"Luojia Tang, Yundi Hu, Hua Wang, Mingquan Chen, Hu Peng, Yan Tang, Xiaolei Lin, Chaoyang Tong","doi":"10.1007/s11239-026-03268-6","DOIUrl":"https://doi.org/10.1007/s11239-026-03268-6","url":null,"abstract":"<p><p>To verify the scientific, robust and generalizable application of Pulmonary Embolism Comprehensive Screening Scoring (PECSS) in the clinical screening of pulmonary embolism among multi-center emergency cohorts. PECSS were previously derived using emergency cohort from Zhongshan Hospital, with screening performances evaluated and compared to Wells score. In this study, suspected pulmonary embolism (PE) patients from 4 major tertiary hospitals in Shanghai were prospectively enrolled from January to June 2024. Screening performances of PECSS and PECSS with D-Dimer were evaluated and compared to traditional Wells Score (WS) methods among these external validation cohorts. Compared to WS, PECSS achieved low mis-diagnosis rates for all PE severity categories among external validation cohorts. When incorporated with D-Dimer, PECSS demonstrated high sensitivity with acceptable range of specificity. The screening performances of PECSS and PECSS + D-Dimer showed high consistency between the derivation and external validation cohorts, as well as across the 4 external validation centers. The newly developed PECSS and PECSS + D-Dimer screening approaches serve as an effective yet practical tool for the clinical screening of acute PE in emergency setting.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stroke-heart syndrome outcomes in pre-existing vs. new-onset dementia: a report from a global federated research network.","authors":"Tianshu Gu, Yang Chen, Akash Mavilakandy, Steven H M Lam, Amir Askarinejad, Riccardo Proietti, Tong Liu, Kang-Yin Chen, Gregory Y H Lip","doi":"10.1007/s11239-026-03389-y","DOIUrl":"https://doi.org/10.1007/s11239-026-03389-y","url":null,"abstract":"<p><p>The prognostic significance of dementia onset in patients with stroke-heart syndrome (SHS) remains uncertain. We compared clinical outcomes between patients with pre-existing and new-onset dementia after ischemic stroke complicated by SHS. This retrospective cohort study used the TriNetX Global Collaborative Network, comprising de-identified electronic health records from more than 130 healthcare organizations between 2000 and 2024. Adults with ischemic stroke and subsequent SHS, defined as acute cardiac complications within 30 days after stroke, were identified and categorized as having pre-existing or new-onset dementia. Propensity score matching was used to balance demographics, comorbidities, and baseline treatments. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals. We identified 7,667 patients with pre-existing dementia and 22,375 with new-onset dementia. After matching, 7,667 pairs were analyzed. Compared with pre-existing dementia, new-onset dementia was associated with a higher 1-year risk of major adverse cardiovascular events (MACE; HR 1.13, 95% confidence interval 1.07-1.19). This excess risk was mainly reflected by recurrent stroke (HR 1.50, 95% CI 1.31-1.72) and heart failure (HR 1.34, 95% CI 1.23-1.47) among MACE components, while atrial fibrillation was also increased as a secondary outcome (HR 1.36, 95% CI 1.25-1.48). Findings were consistent at 2- and 3-year follow-up, among patients with first-ever stroke, and after further adjustment for NIHSS, thrombolysis, and post-stroke rehabilitation. Among patients with SHS, new-onset dementia was associated with higher cardiovascular risk than pre-existing dementia, supporting closer brain-heart-cognition monitoring after stroke.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thrombotic and ischemic event reporting with anticoagulant reversal agents: a multi-agent FAERS pharmacovigilance study.","authors":"Hasan Burak Isleyen, Sevil Tugrul Yavuz, Nusret Acikgoz, Ramazan Ozdemir, Mahmut Uluganyan, Sercan Bulut, Oguzhan Abanoz, Esra Danisman, Ertugrul Okuyan","doi":"10.1007/s11239-026-03395-0","DOIUrl":"https://doi.org/10.1007/s11239-026-03395-0","url":null,"abstract":"<p><p>Anticoagulant reversal is usually performed during severe bleeding in patients who may remain at substantial thrombotic risk. We evaluated thrombotic and ischemic adverse-event reporting for andexanet alfa, idarucizumab, and a prothrombin complex concentrate (PCC) exposure set in the FDA Adverse Event Reporting System (FAERS). Public quarterly FAERS ASCII files from 2018Q2 through 2026Q1 were analyzed according to reporting principles for disproportionality analyses. Reports were deduplicated at case level. The primary exposure definition was primary or secondary suspect (PS/SS) reversal-agent reporting; all-role exposure, core-endpoint, and product/formulation-specific PCC analyses were sensitivity analyses. Exact Medical Dictionary for Regulatory Activities (MedDRA) preferred-term dictionaries defined thrombotic and ischemic endpoints. Reporting odds ratios (RORs), proportional reporting ratios (PRRs), and information component lower bounds (IC025) were calculated. The dataset included 11,586,364 deduplicated reports. PS/SS exposure sets included 1,086 andexanet alfa, 1,163 idarucizumab, and 1,080 PCC reports. The thrombotic/ischemic composite was reported in 371 andexanet reports (ROR 32.72, 95% CI 28.87-37.10), 156 idarucizumab reports (ROR 9.78, 95% CI 8.26-11.57), and 231 PCC reports (ROR 17.16, 95% CI 14.84-19.85). Ischemic stroke was the strongest andexanet component signal (ROR 120.38, 95% CI 103.88-139.49). FAERS reports showed disproportionate thrombotic and ischemic reporting for all three reversal-agent exposure sets, with a prominent andexanet signal for ischemic stroke. These findings are hypothesis-generating and should not be interpreted as incidence, causality, or a direct comparative clinical-risk estimate.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148982772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dabigatran use and cerebrovascular event risk across body mass index in atrial fibrillation: a real-world nested case-control study.","authors":"Karim M Mahawish, Valery Feigin, P Alan Barber, Derrick A Bennett, Rita Krishnamurthi, Harvey D White","doi":"10.1007/s11239-026-03394-1","DOIUrl":"https://doi.org/10.1007/s11239-026-03394-1","url":null,"abstract":"<p><p>Dabigatran is widely used for stroke prevention in atrial fibrillation (AF), but concerns remain regarding its effectiveness in patients with Class III obesity ( BMI ≥40 kg/m2.) We evaluated the association between dabigatran use in patients with AF and ischaemic stroke (IS) or transient ischaemic attack (TIA) across body mass index (BMI) categories in a multiethnic New Zealand population. In this retrospective nested case-control study, cases with incident IS/TIA were identified from the fifth Auckland Regional Community Stroke Study (1st September 2020-31st August 2021), and event-free controls were randomly selected from the National Minimum Dataset. Multivariable logistic regression was used to estimate adjusted odds ratios (aORs) for IS/TIA, and effect modification by BMI catergory (< 30, 30-39.9, ≥40 kg/m²) was assessed using an interaction term. Among 1,854 patients with AF (295 cases, 1,559 controls), dabigatran use was associated with lower odds of IS/TIA (adjusted odds ratio [aOR] 0.50, 95% CI 0.38-0.68). After multivariable adjustment, BMI was not independently associated with IS/TIA risk. The association between dabigatran use and lower IS/TIA risk was similar in patients with BMI <30 and 30-39.9 kg/m², but the point estimate shifted towards the null in patients with BMI ≥40 kg/m² and was imprecise. There was no statistical evidence of effect modification by BMI (p-interaction=0.49), although clinically important attenuation in Class III obesity could not be excluded. In this real-world nested case-control study, there was no clear statistical evidence of BMI-related effect modification; however, the study had limited power in patients with BMI ≥40 kg/m², and clinically important attenuation, including the possibility of no reduction in IS/TIA odds with dabigatran use in Class III obesity cannot be excluded.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-dose rivaroxaban versus warfarin in Asian patients after surgical bioprosthetic valve replacement: a propensity score-matched and inverse probability-weighted real-world study.","authors":"Rui Guo, Dan Zhang, Fuyang Mei, Leping Hou, Ying Luo, Dan Luo","doi":"10.1007/s11239-026-03393-2","DOIUrl":"https://doi.org/10.1007/s11239-026-03393-2","url":null,"abstract":"<p><p>Evidence for rivaroxaban during the early postoperative period after surgical bioprosthetic valve replacement remains limited, particularly in Asian patients receiving low-dose rivaroxaban. We compared the effectiveness and safety of low-dose rivaroxaban versus dose-adjusted warfarin within the initial 3 months after surgery. In this single-center retrospective cohort study, we included consecutive adults who underwent surgical bioprosthetic valve replacement between August 2021 and December 2023 and received postoperative oral anticoagulation with low-dose rivaroxaban (15 or 10 mg once daily) or warfarin. Propensity score matching was used as the primary analysis, and inverse probability of treatment weighting was performed as a sensitivity analysis. The primary effectiveness outcome was thromboembolic events; the primary safety outcome was clinically relevant bleeding. Time-to-event outcomes were analyzed using Cox proportional hazards models, and absolute risk differences were reported descriptively. A total of 367 patients were included (178 rivaroxaban, 189 warfarin). After 1:1 PSM, 125 pairs were analyzed. During the 3-month follow-up, thromboembolic events occurred in 1/125 patients (0.8%) in each group, with an absolute risk difference of 0.0% points. Clinically relevant bleeding occurred in 7/125 patients (5.6%) in the rivaroxaban group and 11/125 patients (8.8%) in the warfarin group, with an absolute risk difference of -3.2% points. The composite outcome occurred in 8/125 (6.4%) and 12/125 (9.6%) patients, respectively, with an absolute risk difference of -3.2% points. The confidence interval for thromboembolic events was very wide, indicating substantial imprecision. Sensitivity analysis using IPTW yielded directionally consistent results. During the first 90 days after surgical bioprosthetic valve replacement, no statistically significant differences in thromboembolic or clinically relevant bleeding outcomes were detected between low-dose rivaroxaban and warfarin. However, thromboembolic events were very rare and the effectiveness analysis was substantially underpowered. These findings should be considered exploratory and hypothesis-generating, and larger prospective studies are needed to provide more precise estimates.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of tranexamic acid in patients undergoing hip hemiarthroplasty: an updated systematic review and meta-analysis.","authors":"Umama Alam, Muhammad Asad Asif, F N U Mainka, Iftikhar Khan, Zonaira Mushahid, Talha Bin Tariq, Muhammad Ansab, Fatima Sajjad, Mohammad Ahmer Minhaj, Ibadullah Tahir, Kainat Sheraz, Muhammad Abdullah Awan, Kanza Ahmed, Hafsa Khalil, Abdul Rehman Shahid, Hassan Hanif, Areeba Kashif, Fazeela Bibi","doi":"10.1007/s11239-026-03391-4","DOIUrl":"https://doi.org/10.1007/s11239-026-03391-4","url":null,"abstract":"<p><p>Hip hemiarthroplasty for femoral neck fractures is often associated with substantial perioperative blood loss and transfusion requirements. Tranexamic acid (TXA) may reduce bleeding, but concerns remain regarding thromboembolic safety. This systematic review and meta-analysis evaluated the efficacy and safety of TXA in hip hemiarthroplasty. PubMed, Embase, and Cochrane were searched from inception to February 2026. Randomized controlled trials and cohort studies comparing TXA with no TXA or no TXA in patients undergoing hip hemiarthroplasty were included. Random-effects meta-analyses were performed to pool risk ratios (RRs) and mean differences (MDs), with subgroup and sensitivity analyses conducted to assess the robustness of the findings. The primary outcome was total blood loss. Secondary outcomes included postoperative haemoglobin, transfusion requirement, mortality, thromboembolic events, surgical site infection, stroke MI and length of hospital stay. Although total blood loss was the pre-specified primary outcome, transfusion requirement was also evaluated as an important secondary outcome because of its direct clinical relevance. Fourteen studies comprising 7,660 patients (3,271 TXA and 4,389 controls) were included. TXA significantly reduced allogeneic transfusion requirements (RR 0.48, 95% CI 0.38-0.61; P<0.001) and improved postoperative day-1 haemoglobin (MD 0.48 g/dL, 95% CI 0.14-0.83; P=0.011). A reduction in 30-day mortality (RR 0.69, 95% CI 0.49-0.96; P=0.029) and length of hospital stay (MD -1.57 days, 95% CI -3.12 to -0.03; P=0.047) was observed, although both findings were sensitive to individual studies and should be interpreted cautiously. Total blood loss was not significantly different between groups (MD -162.73 mL, 95% CI -346.49 to 21.02; P=0.076) because of extreme heterogeneity. TXA was not associated with an increased risk of DVT, PE, MI, stroke, or surgical site infection. No significant differences were observed between intravenous and intra-articular administration. TXA is an effective and safe adjunct in patients undergoing hip hemiarthroplasty. It significantly reduces transfusion requirements and preserves early postoperative haemoglobin without increasing major postoperative complications. Although reductions in 30-day mortality and length of hospital stay were observed, these findings require cautious interpretation because they were less robust and largely derived from observational evidence. Further high-quality randomized controlled trials are warranted to confirm these potential benefits.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Venous thromboembolism mortality trends among us adults with cancer, 1999-2024.","authors":"Gang Li, Xue Zhang, Guanbo Zhang, Jinsong Li, Jiaxing Wang, Zhijian Chen, Qingbin Zeng","doi":"10.1007/s11239-026-03392-3","DOIUrl":"https://doi.org/10.1007/s11239-026-03392-3","url":null,"abstract":"<p><p>Venous thromboembolism (VTE) remains a leading preventable cause of death among cancer patients in the United States. Despite advances in thromboprophylaxis and clinical guideline development, nationally representative longitudinal data on VTE-related mortality trends in this population remain limited. Using CDC WONDER multiple-cause-of-death records (1999-2024), we identified VTE-related deaths (ICD-10: I26, I80-I82) among US adults aged ≥ 25 years with a concurrent cancer diagnosis (C00-C97). Age-adjusted mortality rates (AAMRs) per 100,000 persons and average annual percent changes (AAPCs) with 95% confidence intervals were estimated using Joinpoint regression and stratified by sex, race/ethnicity, age group, urbanization level, Census region, and state. Among 312,260 VTE-related cancer deaths, the national AAMR rose from 3.92 to 7.58 per 100,000 (AAPC: 2.40%; p < 0.001), with the sharpest acceleration during 2019-2022 (APC: 12.78%; p = 0.031). Increases were statistically significant across all demographic and geographic subgroups, though the magnitude varied considerably. By sex, mortality rose more steeply among women (AAPC: 2.61%; p < 0.001) than men (AAPC: 2.14%; p < 0.001). By race/ethnicity, the fastest increases occurred among non-Hispanic American Indian/Alaska Native (3.73%; p < 0.001), non-Hispanic Asian/Pacific Islander (3.62%; p < 0.001), Hispanic (3.12%; p < 0.001), and non-Hispanic Black (3.07%; p < 0.001) populations, compared with non-Hispanic White individuals, who showed the slowest rise (2.45%; p < 0.001). By age group, AAPCs ranged from 2.09% among adults 55-64 years (p < 0.001) to 4.19% among those ≥ 85 years (p < 0.001), indicating a disproportionate burden among the oldest patients. By Census region, the West (3.02%; p < 0.001) and South (2.70%; p < 0.001) exhibited faster growth than the Midwest (2.33%; p < 0.001) and Northeast (2.13%; p < 0.001). At the state level, AAPCs ranged from - 2.76% in Maine (p = 0.034), the only state with a significant decline, to 6.15% in Colorado (p < 0.001), with 39 of 51 jurisdictions showing statistically significant increases. VTE-related mortality among US adults nearly doubled from 1999 to 2024. A marked surge was observed during the COVID-19 pandemic, followed by stabilization after 2022. Persistent disparities across demographic and geographic subgroups underscore the urgent need for equity-oriented prevention strategies.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Meta-analysis of imaging techniques for the diagnosis of left ventricular thrombus following acute myocardial infarction.","authors":"Christopher Junyan Low, Aloysius Sheng-Ting Leow, Yao Neng Teo, Yao Hao Teo, Nicholas L Syn, Fang-Qin Goh, Jamie Sin-Ying Ho, Benjamin Yong-Qiang Tan, Leonard Leong-Litt Yeo, Raymond Ching-Chiew Wong, Ping Chai, Tiong-Cheng Yeo, Mark Yan-Yee Chan, Ching-Hui Sia","doi":"10.1007/s11239-026-03387-0","DOIUrl":"https://doi.org/10.1007/s11239-026-03387-0","url":null,"abstract":"<p><p>Left ventricular thrombus (LVT) can occur in patients after acute myocardial infarction (AMI) and carries significant embolic risk. Leveraging imaging tools that can guide the early and accurate diagnosis of LVT and appropriate use of anti-thrombotic therapy can mitigate the risk of embolic events. This study aims to evaluate the utility of common imaging modalities for the diagnosis of LVT in post-AMI patients. Several databases (Medline, Embase and Cochrane Library) were searched until May 2025 for studies reporting on the comparative diagnostic performance of imaging modalities for LVT in post-AMI patients. Fourteen studies were identified for inclusion. Compared to delayed enhancement cardiac magnetic resonance imaging (DE-CMRI), transthoracic echocardiography (TTE) with or without contrast and cine-CMRI all had high specificity and contrast TTE had the highest sensitivity for LVT detection. A strategy to identify high-risk patients who would benefit from further imaging with CMRI to identify LVT should be considered for patients whose TTE is inconclusive.</p>","PeriodicalId":17546,"journal":{"name":"Journal of Thrombosis and Thrombolysis","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148865547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}